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examination and laboratory data. In this cohort, we evaluated
QOL of RA patients using EQ-5D, and then analyzed the factors
that inﬂuenced on EQ-5D by the analysis of variance. The factors
analyzed here were gender, age, disease duration, disease activity,
disability, and comorbidity. RESULTS: In September 2007, a
total 5,023 RA patients (female 84.2%, average 58.0 years-old,
average disease duration 11.3 years, rheumatoid factor positive
74.8%, patients taking steroid, methotrexate and biologics were
51.0%, 63.6%, and 4.3%, respectively) answered the question-
naire of EQ-5D. The factors aand the percentage of their contri-
butions on EQ-5D were as follows; i) disability assessed by
JHAQ (Japanese Health Assessment Questionnaire): 57.6%,
pain VAS (visual analog scale): 12.5%, female: 6.1%, joint
surgery: 5.9%, non-orthopedic surgery: 5.4%, duration of
disease: 1.8% and occurrence of fractures: 1.3%. CONCLU-
SIONS: QOL of RA patients is deeply inﬂuenced by the disability
together with comorbidity. Management for the control of both
disease activity and comorbidity is crucial.
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OBJECTIVES: The French public health law of 9 August 2004
took this need into consideration and provided for the imple-
mentation of a quality of life improvement programme for those
affected by chronic illnesses. Furthermore, the 87th of the 110
Public Health objectives is aimed at “Improving the quality of
life of those suffering from osteoarthritis” Describe what impact
treating sufferers of osteoarthritis has on their quality of life.
METHODS: Quality of life was also evaluated for subjects suf-
fering from gonarthritis using the SF-12 score, which is an
approved generic tool for determining the physical and mental
state of health of populations. RESULTS: A total of 256 subjects
suffering from gonarthritis were randomised into 2 groups: 127
randomised subjects were placed in the group treated with ACS
Avian, and 129 randomised subjects in the group receiving the
placebo. Upon inclusion, the PCS-12 scores were 36.43 and
36.64 for the group treated with ACS Avian and the group
receiving the placebo respectively. The 2 groups were similar
upon inclusion. After 6 months of treatment, the PCS-12 scores
were 42.25 and 39.47 for the group treated with ACS Avian and
the group receiving the placebo respectively. There was a statis-
tically signiﬁcant improvement in the physical dimension score
of the group of patients treated with ACS Avian compared with
that of the placebo group (p < 0.05). CONCLUSIONS: These
various studies conﬁrm the sharp deterioration in the physical
dimension of quality of life of patients with gonarthritis. There
was a statistically signiﬁcant improvement in the physical dimen-
sion score of the group of patients treated with ACS Avian
compared with that of the placebo group. This data conﬁrms the
pertinence of both the public health objective ﬁxed by the health
authorities, and the use of ACA Avian in the treatment of
osteoarthritis.
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OBJECTIVES: Over the last few years, in addition to traditional
mortality and morbidity indexes, new measuring instruments
for assessing state of health have been developed. One of the
applications of these new instruments is the self-assessment, by
patients, of their state of health. Quality of life is therefore
readily taken into consideration today when assessing state of
health, whether in terms of understanding the consequences of
a pathology, comparing the impact of alternative strategies, or
evaluating the effect of health policies. The 87th of the 110
public health objectives is aimed at “Limiting the disability and
improving the quality of life of those suffering from osteoarthri-
tis” Compare the level of quality of life in sufferers of osteoar-
thritis with that of the population in general and other
pathologies. METHODS: In order to evaluate the quality of life
of osteoarthritis patients, SF-12 scores were calculated for 301
patients suffering from femorotibial gonarthritis and 1,945 rep-
resentative subjects of the French population aged 15 and over.
The SF-12 score is a generic tool used to assess the physical and
mental state of health of populations. The higher the score, the
better the quality of life. RESULTS: The average PCS-12 score
was considerably lower in osteoarthritis patients (36.08  7.88)
compared with that of the population in general (49.87  8.32).
MCS-12 scores were similar for both populations (48.88 
10.24 and 46.77  9.69 respectively). There was a strong cor-
relation between PCS-12 scores and those of the Lequesne algo-
functional index (p < 0.0001), knee pain at rest (p = 0.0013) and
in activity (p < 0.0001). There was a strong correlation between
MCS-12 scores and those of the Lequesne index (p < 0.003), and
at the limitation of the walking perimeter in particular. For
comparison purposes, PCS-12 and MCS-12 scores for an Ameri-
can population were 46.47 and 52.99 respectively for hyperten-
sion, 40.02 and 51.15 for a cardiac accident, and 44.84 and
52.49 for type II diabetes. Little SF-12 data exists in France. A
study carried out in 2002 on the benign hypertrophy of the
prostate (BHP) gave PCS-12 and MCS-12 scores of 46 and 47.2
respectively. CONCLUSIONS: These studies conﬁrm the sharp
deterioration in the quality of life of patients with gonarthritis,
both compared with the population in general and compared
with patients affected by other chronic pathologies. Deteriora-
tion of the physical dimension was observed, associated with
pain and functional disability. The mental dimension of quality
of life seemed less affected, and was associated with the limita-
tion of the walking perimeter. This data conﬁrms the pertinence
of the 87th public health objective.
PMS54
RELIEF OF PAIN AND SYMPTOMS IN KNEE CARTILAGE
DEFECT IS ASSOCIATED WITH HIGHER SF-36 UTILITY
SCORES: DATA FROM A PROSPECTIVE RANDOMIZEDTRIAL
OF CHONDROCELECT®
Gerlier L1, Lamotte M1,Van Lommel N2,Wille M3,Vanlauwe JJ4
1IMS Health, Brussels, Belgium, 2TiGenix NV, LEUVEN, Belgium,
3TiGenix NV, Leuven, Belgium, 4University Hospitals Leuven,
Pellenberg, Belgium
OBJECTIVES: Characterized Chondrocytes Implantation (CCI),
a knee cartilage repair technique using an autologous cell therapy
product (ChondroCelect®), results in better structural repair
than microfracture as demonstrated in a prospective randomized
clinical trial (Saris, Vanlauwe et al. 2008). The SF-36 question-
naire collected along the trial allowed the calculation of utility
scores. This analysis aims to quantify the gap in utility levels by
surgery outcome. METHODS: Patients were split by response
status to the self-reported Knee injury and Osteoarthritis
Outcome Score (KOOS) and pain Visual Analog Scale (VAS)
regardless of the treatment received. Utility scores were derived
from the SF-36 via a validated algorithm and compared between
responders (overall KOOS increase >=10%, VAS decrease
>=20% vs. baseline) and non-responders at Months 24, 30 and
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36 post-surgery using the Mann-Whitney test. Pearson correla-
tion coefﬁcients were calculated between utility scores and the
KOOS overall, KOOS quality of life and VAS scores at each
time-point. RESULTS: Signiﬁcantly higher utility scores were
observed in KOOS responders compared to non-responders at
Months 30 (0.817 vs. 0.691, n = 25/14, p = 0.004) and 36 (0.775
vs. 0.618, n = 19/6, p = 0.006) and in VAS responders compared
to non-responders at Months 24 (0.827 vs. 0.701, n = 17/9,
p = 0.038) and 36 (0.764 vs. 0.600, n = 21/4, p = 0.015). A
similar trend of borderline signiﬁcance was measured at Months
24 (using KOOS, 0.818 vs. 0.728, n = 16/10, p = 0.136) and 30
(using VAS, 0.800 vs. 704, n = 21/4, p = 0.053). Utility scores
correlated best with the KOOS overall (Pearson coefﬁcients
ranged from 0.579 to 0.721, p-values < 0.01) and VAS scores
(-0.514 to -0.671, p-values < 0.01). CONCLUSIONS: Gaps in
utility scores between responders (= successful surgery) and non-
responders ranged from 0.091 to 0.164. This ﬁnding validates
the assumption made in a previous Health Technology Assess-
ment on Autologous Chondrocytes Implantation. Consistent
gaps and signiﬁcant correlations with validated tools provide
valuable information for future economic modeling of CCI.
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OBJECTIVES: QOL (quality of life) is critical in the manage-
ment of patients with rheumatoid arthritis (RA). To evaluate the
QOL of RA patients with different background, we evaluated the
QOL by using Japanese version of EuroQol (EQ-5D) in a large
observational cohort study of Japanese RA patients, IORRA.
METHODS: We have established a large observational cohort of
RA patients IORRA (Institute Of Rheumatology Rheumatoid
Arthritis) in the Institute of Rheumatology Tokyo Women’s
Medical University since 2000. Essentially all RA patients who
consulted there were registered, and clinical parameters including
the disease activity, use of drugs and the occurrence of adverse
events in daily clinical settings were assessed biannually based on
patient’s report, physician’s examination and laboratory data. In
this cohort, we evaluated the QOL of RA patients by EQ-5D,
disease activity by DAS28, and disability by JHAQ, and then we
analyzed the related factors for EQ-5D by Spearman’s correla-
tion. RESULTS: In September 2007, a total 5023 RA patients
(female 84.2%, average 58.02 years-old, average disease dura-
tion 11.26 years, rheumatoid factor positive 74.8%, patients
taking steroid, methotrexate and biologics were 51.0%, 63.6%,
and 4.3%, respectively) fulﬁlled the questionnaire of EQ-5D.
Mean  SD of EQ-5D, DAS28 and JHAQ was 0.757  0.178,
3.28  1.147 and 0.737  0.769, respectively, EQ-5D was
worse in female (0.75  0.177) than in male (0.798  0.177)
patients, and worse in rheumatoid factor positive (0.75  0.178)
than negative (0.782  0.175) patients. EQ-5D became worse by
older age and longer disease duration. No clear relationship was
identiﬁed between EQ-5D and medications including corticoster-
oid, methotrexate or biologics in this cross-sectional analysis.
CONCLUSIONS: EQ-5D based QOL was analyzed in a large
number of Japanese RA patients using IORRA cohort.
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OBJECTIVES: The absence of objective signs and lack of tests
make patient complaints fundamental to a presumptive diagnosis
of ﬁbromyalgia. To make diagnosis easier, H. Moldofsky has
developed a questionnaire of 6 items related to diffuse pain,
fatigue, psychological distress, unrestorative sleep and impaired
well-being. To validate the FMQ (Fibromyalgia Moldofsky Ques-
tionnaire) as a tool to aid diagnosis,METHODS:A representative
sample of 1500 subjects from the general UK population was
constituted using the quotamethod. The FMQquestionnaire, was
administered along with two validated questionnaires (LFESSQ
London Fibromyalgia Epidemiology Study Screening Question-
naire and CES-D Center for Epidemiologic Studies Depression
Scale) and a questionnaire assessing a decline in the restorative
effects of sleep (SQA Sleep Quality Assessment). The maximum
score of 18 reﬂected a strong presumption of ﬁbromyalgia
syndrome. Internal consistency, structural and clinical validity
were tested. The sensitivity and speciﬁcity were also assessed,
RESULTS: Internal consistency was satisfactory (aCronbach > 0.7).
The items composing each dimensionwere pertinent to the dimen-
sion that they represented (R > 0.4) and were not correlated with
any other dimension. Subjects responding positively on the
LFESSQ had an FMQ score that was signiﬁcantly higher than
subjects who responded negatively (8.6 [7.9–9.3] vs 4.1 [3.9–4.3],
p < 0.001). Similar differences were observed between those sub-
jects who had or did not have probable depressive symptoms (8.0
[7.4–8.6] vs 4.0 [3.8–4.2], p < 0.001) and between subjects expe-
riencing a decline in the restorative effect of sleep or not (7.3
[7.0–7.6] vs 3.5 [3.3–3.7], p < 0.001).The FMQ had a sensitivity
of 46 to 54%, depending on the speciﬁc dimension and question-
naire studied. Speciﬁcity was optimal (90 to 95%), CONCLU-
SIONS: The results observed during this psychometric validation
showed that the FMQ questionnaire responded to the objectives
that we had established and therefore allows referring physicians
to send subjects with presumed ﬁbromyalgia to specialist investi-
gation centres.
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OBJECTIVES: To determine the validity and responsiveness of
the novel disease-speciﬁc Work Productivity Survey (WPS-RA) in
patients with active rheumatoid arthritis (RA). The WPS-RA
captures the RA impact on work and home-related.productivity.
METHODS: A total of 220 RA subjects were randomized to
400 mg of subcutaneous certolizumab pegol or placebo every 4
weeks, for 24 weeks (wks). The WPS-RA was completed monthly
starting Baseline (BL) until withdrawal/completion. Validity was
evaluated at BL, using the known-groups approach. Mean
WPS-RA responses at BL were compared between subjects with
different levels of physical function or health-related quality-of-
life (HRQoL). Groups were deﬁned by the median-cut of sub-
jects’ scores to Health Assessment Questionnaire Disability Index
(HAQ-DI) and SF-36 (the physical and mental component sum-
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